NextCure (NXTC) Research & Development (2018 - 2026)
NextCure (NXTC) posted quarterly Research & Development of $6.8 million for Q1 2026, down 13.45% year-over-year from $7.9 million in Q1 2025, and little changed quarter-over-quarter from $6.8 million in Q4 2025.
NextCure (NXTC) Research & Development (2018 - 2026) Analysis & Trends
NextCure's Research & Development history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 13.45% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $43.9 million (up 15.47% YoY), while the FY2025 annual figure was $44.9 million, up 8.28% from the prior year.
- Research & Development for Q1 2026 stood at $6.8 million, roughly flat from $6.8 million in the prior quarter.
- The five-year high for Research & Development was $24.1 million in Q2 2025, with the low at $6.1 million in Q3 2025.
- The 5-year median for Research & Development is $11.6 million (2023), against an average of $11.5 million.
- Peak annual rise in Research & Development reached 94.0% in 2025, while the deepest fall reached 30.72% in 2025.
- NextCure's Research & Development stood at $12.8 million in 2022, then decreased by 7.76% to $11.8 million in 2023, then retreated by 24.73% to $8.9 million in 2024, then dropped by 23.61% to $6.8 million in 2025, then gained by 0.5% to $6.8 million in 2026.
- Business Quant data shows NXTC's Research & Development at $6.8 million in Q1 2026, $6.8 million in Q4 2025, and $6.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 7.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.43 Mn |
| Mar 31, 2026 | 6.83 Mn |
| Dec 31, 2025 | 6.80 Mn |
| Sep 30, 2025 | 6.14 Mn |
| Jun 30, 2025 | 24.09 Mn |
| Mar 31, 2025 | 7.90 Mn |
| Dec 31, 2024 | 8.90 Mn |
| Sep 30, 2024 | 8.77 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 11.40 Mn |
| Dec 31, 2023 | 11.83 Mn |
| Sep 30, 2023 | 11.01 Mn |
| Jun 30, 2023 | 13.45 Mn |
| Mar 31, 2023 | 11.65 Mn |
| Dec 31, 2022 | 12.82 Mn |
| Sep 30, 2022 | 13.53 Mn |
| Jun 30, 2022 | 12.83 Mn |
| Mar 31, 2022 | 15.02 Mn |
| Dec 31, 2021 | 12.26 Mn |
| Sep 30, 2021 | 13.60 Mn |